Yuan-Deng Luo
Overview
Explore the profile of Yuan-Deng Luo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
66
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lin X, Luo Y, Mao C, Gong Y, Hou Y, Zhang L, et al.
Hepatology
. 2024 Sep;
PMID: 39348425
Background And Aims: Patients with aggressive HCC have limited therapeutic options. Therefore, a better understanding of HCC pathogenesis is needed to improve treatment. Genomic studies of HCC have improved our...
2.
Zhang J, Lin X, Yu H, Fang L, Wu D, Luo Y, et al.
Exp Mol Med
. 2023 Oct;
55(10):2281-2286.
PMID: 37783772
No abstract available.
3.
Zhang J, Lin X, Yu H, Fang L, Wu D, Luo Y, et al.
Exp Mol Med
. 2023 Aug;
55(10):2162-2176.
PMID: 37653031
Metastatic hepatocellular carcinoma (HCC) is the most lethal malignancy and lacks effective treatment. FBXL6 is overexpressed in human hepatocellular carcinoma (HCC), but whether this change drives liver tumorigenesis and lung...
4.
Luo Y, Liu X, Fang L, Yu H, Zhang Y, Chen M, et al.
Theranostics
. 2022 Dec;
12(18):7903-7919.
PMID: 36451866
Abnormal activation of mTOR through loss of tuberous sclerosis complex (Tsc) frequently occurs in hepatocellular carcinoma (HCC). Mutant Kras could induce aggressive HCCs. Here, we aim to identify the predictive...
5.
Tan Y, Lin X, Luo Y, Zhang J, Fang L, Zhu Y, et al.
Oncol Lett
. 2020 Sep;
20(5):216.
PMID: 32963622
Aberrantly low expression of NF-κB inhibitor α (IκBα) is observed in hepatocellular carcinoma (HCC), yet the underlying mechanism via which IκBα regulates HCC remains largely unknown. Therefore, to determine the...
6.
Luo Y, Fang L, Yu H, Zhang J, Lin X, Liu X, et al.
J Hepatol
. 2020 Aug;
74(1):96-108.
PMID: 32738450
Background & Aims: p53 mutations occur frequently in human HCC. Activation of the mammalian target of rapamycin (mTOR) pathway is also associated with HCC. However, it is still unknown whether...
7.
Luo Y, Yu H, Liu X, Huang D, Dai H, Fang L, et al.
Cancer Med
. 2020 Apr;
9(12):4083-4094.
PMID: 32293796
Purpose: Hepatocellular carcinoma (HCC) is a common malignant cancer and the third leading cause of death worldwide. The molecular mechanism of HCC remains unclear. Recent studies have demonstrated that the...
8.
Luo Y, Zhang J, Fang L, Zhu Y, You Y, Zhang C, et al.
Carcinogenesis
. 2019 Aug;
41(5):689-698.
PMID: 31400758
Hepatocellular carcinoma (HCC) is reported to associate with abnormal expression of SCF E3 ubiquitin ligases. FBXW10, an F-box protein of the E3 ubiquitin ligases, was abnormally regulated in HCC patients....